Sensus Healthcare, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sensus Healthcare, Inc.
Sensus announced top-line results from a five-year restrospective study of its SRT-100 Superficial Radiation Therapy device for non-melanoma skin cancer. SRT-100 received a 510(k) in 2018.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
After a lackluster first quarter, the medtech IPO scene is gradually livening up with several companies their shares successfully floated on the public markets for the first time in the second quarter. But activity levels are still a far cry from the bonanza of 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2016.
- Medical Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices